Among EGFR ex20ins patients, 21/84 (25%) had tumours with PD-L1 greater or equal to 50%, 25/84 (30%) had 1–49% PD-L1, and 30/84 (36%) had PD-L1 < 1%. This evidence concerns the gene EGFR and neoplasm.